Glucagon-like peptides 1 and 2: intestinal hormones implicated in the pathophysiology of mucositis

Research output: Contribution to journal › Review › Research › peer-review

Standard

Glucagon-like peptides 1 and 2 : intestinal hormones implicated in the pathophysiology of mucositis. / Kissow, Hannelouise.

In: Current Opinion in Supportive and Palliative Care, Vol. 9, No. 2, 2015, p. 196-202.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Kissow, H 2015, 'Glucagon-like peptides 1 and 2: intestinal hormones implicated in the pathophysiology of mucositis', Current Opinion in Supportive and Palliative Care, vol. 9, no. 2, pp. 196-202. https://doi.org/10.1097/SPC.0000000000000132

APA

Kissow, H. (2015). Glucagon-like peptides 1 and 2: intestinal hormones implicated in the pathophysiology of mucositis. Current Opinion in Supportive and Palliative Care, 9(2), 196-202. https://doi.org/10.1097/SPC.0000000000000132

Vancouver

Kissow H. Glucagon-like peptides 1 and 2: intestinal hormones implicated in the pathophysiology of mucositis. Current Opinion in Supportive and Palliative Care. 2015;9(2):196-202. https://doi.org/10.1097/SPC.0000000000000132

Author

Kissow, Hannelouise. / Glucagon-like peptides 1 and 2 : intestinal hormones implicated in the pathophysiology of mucositis. In: Current Opinion in Supportive and Palliative Care. 2015 ; Vol. 9, No. 2. pp. 196-202.

Bibtex

@article{c46d4020dbbe40ac9626812d97ec38cf,
title = "Glucagon-like peptides 1 and 2: intestinal hormones implicated in the pathophysiology of mucositis",
abstract = "PURPOSE OF REVIEW: Chemotherapy often causes adverse effects, including pain, bloating, diarrhea, and inflammation and ulceration of the mucous membranes lining the digestive tract, which are collectively referred to as mucositis. Unfortunately, no remedy has been found yet to manage these side-effects.RECENT FINDINGS: The intestinal glucagon-like peptide-2 (GLP-2) is secreted from the intestinal endocrine L cells after nutrient intake, but recent findings show that the peptide concentration in the plasma also rises after intestinal injury and that GLP-2 receptor activation is crucial for intestinal healing. The antidiabetic hormone GLP-1, cosecreted with GLP-2, diminished mucositis in an animal model of the condition. Therefore, both peptides could be involved in the pathophysiology of mucositis.SUMMARY: The intestinal GLPs have shown beneficial effects in experimental trials and have potential for therapeutic use. In type 2 diabetic and obese patients, GLP secretion is impaired. Elucidating the role of these endogenous hormones could lead to the identification of mucositis risk factors and an alternative preventive therapy for these patients.",
author = "Hannelouise Kissow",
year = "2015",
doi = "10.1097/SPC.0000000000000132",
language = "English",
volume = "9",
pages = "196--202",
journal = "Current Opinion in Supportive and Palliative Care",
issn = "1751-4258",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "2",

}

RIS

TY - JOUR

T1 - Glucagon-like peptides 1 and 2

T2 - intestinal hormones implicated in the pathophysiology of mucositis

AU - Kissow, Hannelouise

PY - 2015

Y1 - 2015

N2 - PURPOSE OF REVIEW: Chemotherapy often causes adverse effects, including pain, bloating, diarrhea, and inflammation and ulceration of the mucous membranes lining the digestive tract, which are collectively referred to as mucositis. Unfortunately, no remedy has been found yet to manage these side-effects.RECENT FINDINGS: The intestinal glucagon-like peptide-2 (GLP-2) is secreted from the intestinal endocrine L cells after nutrient intake, but recent findings show that the peptide concentration in the plasma also rises after intestinal injury and that GLP-2 receptor activation is crucial for intestinal healing. The antidiabetic hormone GLP-1, cosecreted with GLP-2, diminished mucositis in an animal model of the condition. Therefore, both peptides could be involved in the pathophysiology of mucositis.SUMMARY: The intestinal GLPs have shown beneficial effects in experimental trials and have potential for therapeutic use. In type 2 diabetic and obese patients, GLP secretion is impaired. Elucidating the role of these endogenous hormones could lead to the identification of mucositis risk factors and an alternative preventive therapy for these patients.

AB - PURPOSE OF REVIEW: Chemotherapy often causes adverse effects, including pain, bloating, diarrhea, and inflammation and ulceration of the mucous membranes lining the digestive tract, which are collectively referred to as mucositis. Unfortunately, no remedy has been found yet to manage these side-effects.RECENT FINDINGS: The intestinal glucagon-like peptide-2 (GLP-2) is secreted from the intestinal endocrine L cells after nutrient intake, but recent findings show that the peptide concentration in the plasma also rises after intestinal injury and that GLP-2 receptor activation is crucial for intestinal healing. The antidiabetic hormone GLP-1, cosecreted with GLP-2, diminished mucositis in an animal model of the condition. Therefore, both peptides could be involved in the pathophysiology of mucositis.SUMMARY: The intestinal GLPs have shown beneficial effects in experimental trials and have potential for therapeutic use. In type 2 diabetic and obese patients, GLP secretion is impaired. Elucidating the role of these endogenous hormones could lead to the identification of mucositis risk factors and an alternative preventive therapy for these patients.

U2 - 10.1097/SPC.0000000000000132

DO - 10.1097/SPC.0000000000000132

M3 - Review

C2 - 25872118

VL - 9

SP - 196

EP - 202

JO - Current Opinion in Supportive and Palliative Care

JF - Current Opinion in Supportive and Palliative Care

SN - 1751-4258

IS - 2

ER -

ID: 135646036